BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Southern Research Institute and LSU Health Sciences Center Study Validates Using Imaging to Study the Progression of Parkinson's Disease in Preclinical Animal Studies


7/5/2012 10:31:20 AM

BIRMINGHAM, Ala. and SHREVEPORT, La., July 2, 2012 /PRNewswire-USNewswire/ -- Using preclinical molecular imaging, scientists from Southern Research Institute and LSU Health Sciences Center in Shreveport have published data which could lead to better diagnosis and treatment of Parkinson's disease.

Their study"PET Imaging a MPTP-Induced Mouse Model of Parkinson's Disease Using the Fluoropropyl-Dihydrotetrabenazine Analog [18F]-DTBZ (AV-133)"was published in a recent edition (June 18, 2012) of PLoS ONEan online scientific publication which provides free access to scientific studies that will accelerate progress in science and medicine.

Study findings suggest that MPTP-induced Parkinson's disease in a mouse model is appropriate for following the degeneration of the dopaminergic system and that the[18F]-DTBZ analog is a potentially sensitive radiotracer that can be used to diagnose changes associated with Parkinson's by positron emission technology (PET) imaging in mice.

The paper was co-authored by James Toomey, DVM, and Andrew Penman, Ph.D., of Southern Research Institute in Birmingham, and Michael Mathis, Ph.D., of LSU Health Sciences Center in Shreveport. It is available online at http://dx.plos.org/10.1371/journal.pone.0039041.

Many scientists believe finding the cure for Parkinson's will require a much deeper understanding of what causes the disease.

"This imaging pilot validates a diagnostic approach which could lead to better diagnosis and treatment of Parkinson's disease," said Dr. Penman, Vice President of Drug Development at Southern Research. "By validating this imaging model we can acquire better data faster, more cheaply, and also limit the number of animals required to conduct a study in the search for new drugs to treat this debilitating disease."

"Parkinson's researchers who are working to develop novel therapeutics for this disease now have a new optiona validated, non-invasive model that further quantifies the use of preclinical imaging as a way to follow the degeneration process of Parkinson's disease," said Dr. Mathis, Director, Small Animal Imaging Facility at the LSU Health Sciences Center.

Approximately 60,000 Americans are diagnosed with Parkinson's disease each year, with as many as one million Americans living with Parkinson's. It is estimated that seven to ten million people worldwide are living with Parkinson's disease. The combined direct and indirect cost of Parkinson's including treatment, social security payments and lost income from inability to work is estimated to be nearly $25 billion per year in the U.S. alone. Medication costs for an individual with Parkinson's disease averages $2,500 a year. Therapeutic surgery can cost up to $100,000 per patient.

Southern Research and the LSU Health Sciences Center in Shreveport, along with the Biomedical Research Foundation of Northwest Louisiana, formed a collaborative partnership last year to conduct preclinical imaging studies.

Southern Research conducts both contract research and basic research for clients, providing preclinical drug discovery, development, and clinical trial support services in cancer, infectious diseases, and CNS/neurological disease to pharmaceutical and biotechnology companies. Scientists conduct translational science to invent small molecules and advance them from the design stage to the clinic. Services available include medicinal chemistry, molecular biology, biochemistry, high-throughput screening and a full set of in-house GLP development services including toxicology, ADME/PK, animal models, formulations, and bioanalytical services.

ABOUT SOUTHERN RESEARCH
Southern Research Instituteis a not-for-profit 501(c)(3) scientific research organization founded in 1941 that conducts preclinical drug discovery and development, advanced engineering research in materials, systems development, and environment and energy research. More than 550 scientific and engineering team members support clients and partners in the pharmaceutical, biotechnology, defense, aerospace, environmental and energy industries. Southern Research is headquartered in Birmingham, Ala., with facilities in Wilsonville, Ala., Frederick, Md., and Durham, NC and offices in Huntsville, Ala., New Orleans, La., and Washington, DC.

CONTACT: Rhonda Jung
205-337-9634
Jung@SouthernResearch.org

SOURCE Southern Research Institute


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->